Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Roy S. Herbst, David R. Gandara, Fred R. Hirsch et al. · Clinical Cancer Research · 2015
The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous cell carcinoma (SCC) of the lung. There are no approved targeted therapies specific to advanced lung SCC, although The Cancer Genome Atlas project and similar studies have detected a significant number of somatic gene mutations/amplifications in lung SCC, some of which are targetable by investigational agents. However, the frequency of these changes is low (5%-20%), making recruitment and study conduct challenging in the traditional clinical trial setting. Here, we describe our approach to development of a biomarker-driven phase II/II multisubstudy "Master Protocol," using a common platform (next-generation DNA sequencing) to identify actionable molecular abnormalities, followed by randomization to the relevant targeted therapy versus standard of care.
Cited by 244 works. doi:10.1158/1078-0432.ccr-13-3473
Authors
- Roy S. Herbst
- David R. Gandara
- Fred R. Hirsch
- Mary Weber Redman
- Michael Leo LeBlanc
- Philip C. Mack
- Lawrence Howard Schwartz
- Everett E. Vokes
- Suresh S. Ramalingam
- Jeffrey D. Bradley
- Dana B. Sparks
- Yang Zhou
- Crystal Miwa
- Vincent A. Miller
- Roman Yelensky
- Yali Li
- Jeff D. Allen
- Ellen V. Sigal
- David N. Wholley
- Caroline C. Sigman
References
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Comprehensive molecular profiling of lung adenocarcinoma
- Comprehensive genomic characterization of squamous cell lung cancers
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- Pathology of lung cancer